HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Aquestive Therapeutics and raised the price target from $9 to $10, indicating confidence in the company's future performance.
September 30, 2024 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Aquestive Therapeutics and increased the price target from $9 to $10, suggesting a positive outlook for the company's stock.
The increase in price target from $9 to $10 by HC Wainwright & Co. reflects a positive sentiment and confidence in Aquestive Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price as investors may view the raised target as a sign of potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100